Abstract:Finding candidate cancer genes playing causal roles in carcinogenesis is an important task in cancer research. The non-randomness of the co-mutation of genes in cancer samples can provide statistical evidence for these genes' involvement in carcinogenesis. It can also provide important information on the functional cooperation of gene mutations in cancer. However, due to the relatively small sample sizes used in current high-throughput somatic mutation screening studies and the extraordinary large-scale hypothesis tests, the statistical power of finding co-mutated gene pairs based on high-throughput somatic mutation data of cancer genomes is very low. Thus, we proposed a stratified FDR (False Discovery Rate) control approach, for identifying significantly co-mutated gene pairs according to the mutation frequency of genes. We then compared the identified co-mutated gene pairs separately by pre-selecting genes with higher mutation frequencies and by the stratified FDR control approach. Finally, we searched for pairs of pathways annotated with significantly more between-pathway co-mutated gene pairs to evaluate the functional roles of the identified co-mutated gene pairs. Based on two datasets of somatic mutations in cancer genomes, we demonstrated that, at a given FDR level, the power of finding co-mutated gene pairs could be increased by pre-selecting genes with higher mutation frequencies. However, many true co-mutation between genes with lower mutation rates will still be missed. By the stratified FDR control approach, many more co-mutated gene pairs could be found. Finally, the identified pathway pairs significantly overrepresented with between-pathway co-mutated gene pairs suggested that their co-dysregulations may play causal roles in carcinogenesis. The stratified FDR control strategy is efficient in identifying co-mutated gene pairs and the genes in the identified co-mutated gene pairs can be considered as candidate cancer genes because their non-random co-mutations in cancer genomes are highly unlikely to be attributable to chance.

Identifying Candidate Cancer Genes by Finding Co-Occurring Mutations in Cancer Mutation Profiles

Identifying Candidate Cancer Genes Based on Their Somatic Mutations Co-Occurring with Cancer Genes in Cancer Genome Profiling

[Identifying Candidate Cancer Genes Based on Co-Evolving Gene Modules].

Integrated Multi‐omics Data Analyses for Exploring the Co‐occurring and Mutually Exclusive Gene Alteration Events in Colorectal Cancer

Finding Co-Mutated Genes And Candidate Cancer Genes In Cancer Genomes By Stratified False Discovery Rate Control

Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis

Co-occurring Mutations in Different Genes Can Fuel Oncogenic Signaling and Serve as Metastatic Tumor Markers

Systematic Interpretation of Comutated Genes in Large-Scale Cancer Mutation Profiles

A Network Of Cancer Genes With Co-Occurring And Anti-Co-Occurring Mutations

Molecular Cancer apeutics apeutic Discovery tematic Interpretation of Comutated Genes Ther arge-Scale Cancer Mutation Profiles

Identification of driver pathways in cancer based on combinatorial patterns of somatic gene mutations.

An Effective Method to Identify Cooperation Driver Gene Sets

Identifying cancer genes from cancer mutation profiles by cancer functions

Analysis of Pathway Mutation Profiles Highlights Collaboration Between Cancer-Associated Superpathways

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

Analyzing the Co-Disruption of Functions Related to Lung Adenocarcinoma Based on Gene Ontology

Remarkable Difference of Somatic Mutation Patterns Between Oncogenes and Tumor Suppressor Genes.

Identification of Cancer Trait Genes and Association Analysis under Pan-Cancer

Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer.

The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms

Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability.